Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Total Current Liabilities came in at $20.4 million in Q4 2025, down 25.63% YoY from $27.4 million in Q4 2024, and down 15.27% on a QoQ basis from $24.1 million in Q3 2025.
Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Total Current Liabilities data on file, last reported at $20.4 million in Q4 2025.
- Quarterly Total Current Liabilities fell 25.63% year-over-year to $20.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.4 million (down 25.63% YoY) and the FY2025 annual result came in at $20.4 million, down 25.63% from the prior year.
- Total Current Liabilities slipped to $20.4 million in Q4 2025, from $24.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $39.4 million in Q1 2025 to a low of $7.5 million in Q2 2021.
- A 5-year average of $19.1 million and a median of $16.6 million in 2022 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 110.38% in 2025, down 25.63% in 2025.
- Tracing KROS's Total Current Liabilities over 5 years: stood at $11.8 million in 2021, then soared by 39.68% to $16.5 million in 2022, then jumped by 47.3% to $24.4 million in 2023, then increased by 12.62% to $27.4 million in 2024, then decreased by 25.63% to $20.4 million in 2025.
- The last three Total Current Liabilities figures came in at $20.4 million (Q4 2025), $24.1 million (Q3 2025), and $34.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 12.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.15 Mn |
| Dec 31, 2025 | 20.41 Mn |
| Sep 30, 2025 | 24.09 Mn |
| Jun 30, 2025 | 34.71 Mn |
| Mar 31, 2025 | 39.38 Mn |
| Dec 31, 2024 | 27.45 Mn |
| Sep 30, 2024 | 29.01 Mn |
| Jun 30, 2024 | 21.25 Mn |
| Mar 31, 2024 | 18.72 Mn |
| Dec 31, 2023 | 24.37 Mn |
| Sep 30, 2023 | 16.70 Mn |
| Jun 30, 2023 | 16.10 Mn |
| Mar 31, 2023 | 15.46 Mn |
| Dec 31, 2022 | 16.55 Mn |
| Sep 30, 2022 | 11.53 Mn |
| Jun 30, 2022 | 15.45 Mn |
| Mar 31, 2022 | 11.65 Mn |
| Dec 31, 2021 | 11.85 Mn |
| Sep 30, 2021 | 11.02 Mn |
| Jun 30, 2021 | 7.53 Mn |